Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arabinosyltransferase A (embA) is an essential enzyme in mycobacteria, particularly Mycobacterium tuberculosis, responsible for the polymerization of arabinose into the arabinan domain of arabinogalactan, a crucial component of the mycobacterial cell wall. It functions as a validated drug target, with inhibition leading to cessation of cell wall biosynthesis. Ethambutol, a first-line anti-tuberculosis drug, targets this enzyme and related arabinosyltransferases.
Inhibition of arabinosyltransferase activity, leading to disruption of cell wall biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arabinosyltransferase A (embA).